Abstract
HIV-related comorbidities appear to be related to chronic inflammation, a condition characterizing people living with HIV (PLWH). Prior work indicates that cannabidiol (CBD) might reduce inflammation; however, the genetics underpinning of this effect are not well investigated. Our main objective is to detect gene expression alterations in human peripheral blood mononuclear cells (PBMCs) from PLWH after at least one month of CBD treatment.
We analyze ∼41,000 PBMCs from three PLWH at baseline and after CBD treatment (27-60 days). We obtained a coherent signature, characterized by an anti-inflammatory activity, of differentially expressed genes in myeloid cells.
Our study shows how CBD is associated with alterations of gene expression in myeloid cells after CBD treatment.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT05209867
Funding Statement
This study was funded in part by the State of Florida's Consortium for Medical Marijuana Clinical Outcomes Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research and the authors align to the Declaration of Helsinki. The study protocol was approved by University of Florida's IRB.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
We added extra analyses related to pathways and cell-cell communication.
Data Availability statement
The code to obtain our results is available on github (https://github.com/smarini/CBD_HIV_scRNAseq). Our data are available on GEO (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE228652).





